• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Screening
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

New Data on Needle Free Epinephrine Spray Presented at ACAAI 2024

News
Slideshow

A summary of new data presented at the 2024 American College of Allergy, Asthma & Immunology Annual Scientific Meeting.

ARS Pharmaceuticals is presenting new data October 25 on the first needle-free epinephrine nasal spray (neffy) for treating Type I allergic reactions, at the 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting.

These presentations will showcase a number of posters covering topics such as cardiovascular safety, human factor research for emergency readiness, and real-world data in pediatric patients.

The above slideshow features a snapshot of the presentations being featured at the ACAAI meeting, with links to view the posters.

Recent Videos
Tezepelumab Significantly Reduced Exacerbations in Patients with Severe Asthma, Respiratory Comorbidities
Related Content
FDA Accepts Dupilumab sBLA for Review for Treatment of Chronic Spontaneous Urticaria / Image credit: ©chomplearn 2001/AdobeStock

FDA Accepts Dupilumab sBLA for Review for Treatment of Chronic Spontaneous Urticaria

Sydney Jennings
November 15th 2024
Article

The target action date for the FDA decision is April 18, 2025, according to Sanofi and Regeneron.

FDA May End Use of Oral Phenylephrine as Nasal Decongestant Ingredient in OTC Products

FDA May End Use of Oral Phenylephrine as Nasal Decongestant Ingredient in OTC Products

Grace Halsey
November 8th 2024
Article

A decision on ending use of oral phenylephrine as a nasal decongestant in OTC products will be made following public comment on FDA's proposed order.

Knowledge Gaps in How to Manage Anaphylaxis, Epinephrine Use, Persist for Patients, Even EMS / image credit ©TOImages/stock.adobe.com

Knowledge Gaps in How to Manage Anaphylaxis, Epinephrine Use, Persist for Patients, Even EMS

Grace Halsey
October 28th 2024
Article

ACAAI 2024. Two studies here showed that anaphylaxis protocols for EMS are outdated in many states and that many patients don't know how to use epinephrine.

©Rawpixel/shutterstock.com

sNDA Goes to FDA for neffy 1 mg for Young Children with Type 1 Allergic Reactions

Grace Halsey
September 11th 2024
Article

The needle-free nasal spray, if approved, would be the first new administration method for epinephrine in young children in 35 years.

FDA Approves Neffy as First Nasal Spray for Allergic Reactions: Daily Dose / image credit: ©New Africa/AdobeStock

FDA Approves Neffy as First Nasal Spray for Allergic Reactions: Daily Dose

Sydney Jennings
August 20th 2024
Article

Your daily dose of the clinical news you may have missed.

FDA Approves First Intranasal Epinephrine for Emergency Treatment of Allergic Reactions image credit ©Waldenmarus/stock.adobe.com

FDA Approves First Intranasal Epinephrine for Emergency Treatment of Allergic Reactions

Grace Halsey
August 9th 2024
Article

neffy (epinephrine nasal spray) is the first alternative to epinephrine administered by autoinjector or syringe and is comparable in efficacy to the gold standard.

© 2024 MJH Life Sciences

All rights reserved.